Study identifier:D1449L00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An open, randomised, parallel, three treatment groups, multicentre, phase IV study - in real life - to compare the change in social outcome of quetiapine fumarate (Seroquel®) combined with Cognitive Remediation Therapy to conventional treatment in patients with schizophrenia.
schizophrenia
Phase 4
No
Quetiapine fumarate, conventional treatment for schizophrenia
All
85
Interventional
18 Years - 64 Years
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 quetiapine fumarate | Drug: Quetiapine fumarate oral Other Name: Seroquel |
Active Comparator: 2 Conventional treatment for schizophrenia | Drug: conventional treatment for schizophrenia various standard therapies |
Experimental: 3 quetiapine fumarate + Cognitive Remediation Therapy | Drug: Quetiapine fumarate oral Other Name: Seroquel |